On June 1, 2021, Stemirna announced the closing of a $200 million round of financing, led by China Merchants Capital, HongShan, King Lin investment, and WuXi AppTec, with participation from OrbiMed Advisors, Advantech Capital, Zhejiang Guotong Investment, CMB International Capital, Kelly Yi Fang Capital, Forebright Capital, Tsing Song Capital, and CITIC Securities Company Limited, amongst others.

The funds raised in this financing will be primarily used to accelerate the clinical research of the new coronavirus vaccine, construct GMP production workshops, and expand the research and development pipeline.

CEC Capital Group acted as the lead financial advisor for Stemirna in this transaction.

Stemirna is a leading mRNA drug development company in China, possessing an independently owned mRNA full industry chain technology platform and a formulation structure patent known as LPP technology. Stemirna has independently developed a cloud computing-based platform for antigen analysis, prediction, and sequence optimization. The company also boasts a comprehensive mRNA vaccine analysis and quality control technology platform, along with key technologies and equipment for the large-scale production of mRNA vaccines, capable of producing hundreds of millions of doses annually.